Publications

Export 77 results:
Author Title [ Type(Asc)] Year
Filters: Author is Serge Gauthier  [Clear All Filters]
Journal Article
Gauthier S, Schlaefke S.  2014.  Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials.. Clin Interv Aging. 9:2065-77.
Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ et al..  2016.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.. Lancet. 388(10062):2873-2884.
Florian H, Meier A, Gauthier S, Lipschitz S, Lin Y, Tang Q, Othman AA, Robieson WZ, Gault LM.  2016.  Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.. J Alzheimers Dis. 51(4):1237-47.
Gauthier S, Rountree S, Finn B, LaPlante B, Weber E, Oltersdorf T.  2015.  Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer's Disease: A Randomized Phase 2 Study.. J Alzheimers Dis. 48(2):473-81.
Tourian L, Margolese HC, Gauthier S.  2014.  Donepezil-associated mania in two patients who were using donepezil without a prescription.. J Clin Psychopharmacol. 34(6):753-5.
Zimmer ERigon, Leuzy A, Gauthier S, Rosa-Neto P.  2014.  Developments in Tau PET Imaging.. Can J Neurol Sci. 41(5):547-53.
Gordon MForrest, Lenderking WR, Duhig A, Chandler J, J Lundy J, Miller DS, Piault-Louis E, Doody RS, Galasko D, Gauthier S et al..  2016.  Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase.. Alzheimers Dement. 12(1):75-84.
Mortby ME, Black SE, Gauthier S, Miller D, Porsteinsson A, Smith EE, Ismail Z.  2018.  Dementia clinical trial implications of mild behavioral impairment.. Int Psychogeriatr. 30(2):171-175.
Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H et al..  2016.  Defeating Alzheimer's disease and other dementias: a priority for European science and society.. Lancet Neurol. 15(5):455-532.
Schoemaker D, Buss C, Head K, Sandman CA, Davis EP, M Chakravarty M, Gauthier S, Pruessner JC.  2018.  Corrigendum to "Hippocampus and amygdala volumes from magnetic resonance images in children: Assessing accuracy of FreeSurfer and FSL against manual segmentation"[NeuroImage 129 (2016) 1-14].. Neuroimage. 173:1-2.
Jia J, Gauthier S, Pallotta S, Ji Y, Wei W, Xiao S, Peng D, Guo Q, Wu L, Chen S et al..  2017.  Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease.. Alzheimers Dement. 13(5):592-597.
Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K et al..  2019.  The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study.. Can J Neurol Sci. 46(5):499-511.
Sinyavskaya L, Gauthier S, Renoux C, Dell'Aniello S, Suissa S, Brassard P.  2018.  Comparative effect of statins on the risk of incident Alzheimer disease.. Neurology. 90(3):e179-e187.
Li X, Ba M, Ng KPin, Mathotaarachchi S, Pascoal TA, Rosa-Neto P, Gauthier S.  2018.  Characterizing biomarker features of cognitively normal individuals with ventriculomegaly.. Alzheimers Dement (Amst). 10:12-21.
Gauthier S, Proaño JVoltaire, Jia J, Froelich L, Vester JChristophe, Doppler E.  2015.  Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.. Dement Geriatr Cogn Disord. 39(5-6):332-47.
Laforce R, Rosa-Neto P, Soucy J-P, Rabinovici GD, Dubois B, Gauthier S.  2016.  Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.. Can J Neurol Sci. 43(4):503-12.
Brayet P, Petit D, Baril A-A, Gosselin N, Gagnon J-F, Soucy J-P, Gauthier S, Kergoat M-J, Carrier J, Rouleau I et al..  2017.  Brain perfusion during rapid-eye-movement sleep successfully identifies amnestic mild cognitive impairment.. Sleep Med. 34:134-140.
Gauthier S, Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedetti AL, Shin M, Kang MSu, Li X, Ba M et al..  2017.  Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 89(18):1931.
Lajoie I, Nugent S, Debacker C, Dyson K, Tancredi FB, Badhwar AP, Belleville S, Deschaintre Y, Bellec P, Doyon J et al..  2017.  Application of calibrated fMRI in Alzheimer's disease.. Neuroimage Clin. 15:348-358.
Ba M, Kong M, Li X, Ng KPin, Rosa-Neto P, Gauthier S.  2016.  Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener. 5:20.
Therriault J, Ng KPin, Pascoal TA, Mathotaarachchi S, Kang MSu, Struyfs H, Shin M, Benedet AL, Walpola IC, Nair V et al..  2018.  Anosognosia predicts default mode network hypometabolism and clinical progression to dementia.. Neurology. 90(11):e932-e939.
Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung C-O, Shin M, Wang S, Beaudry T, Kang MS, Soucy J-P et al..  2016.  Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.. Mol Psychiatry.
Pascoal TA, Mathotaarachchi S, Shin M, Park AYeon, Mohades S, Benedet AL, Kang MSu, Massarweh G, Soucy J-P, Gauthier S et al..  2018.  Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.. Eur J Nucl Med Mol Imaging. 45(6):1021-1030.
Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Devanand DP, Gauthier S, Howard R, Lanctôt K, Lyketsos CG et al..  2015.  Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition.. Int Psychogeriatr. 27(1):7-17.
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JLuis, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R et al..  2014.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.. Lancet Neurol. 13(6):614-29.

Pages